학술논문

Impact of PSMA PET on Prostate Cancer Management
Document Type
article
Source
Current Treatment Options in Oncology. 25(2)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Clinical Research
Cancer
Prostate Cancer
Aging
Urologic Diseases
Biomedical Imaging
Networking and Information Technology R&D (NITRD)
Bioengineering
4.2 Evaluation of markers and technologies
Detection
screening and diagnosis
Humans
Male
Antigens
Surface
Neoplasm Staging
Positron Emission Tomography Computed Tomography
Prospective Studies
Prostatic Neoplasms
Radiopharmaceuticals
Prostate-Specific Antigen
Clinical decision-making
Drug therapy
Neoplasm staging
Positron-emission tomography
Prognosis
Prostatic neoplasms
Radiotherapy
Surgery
Theranostic nanomedicine
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
Opinion statementPSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.